Characterization of BRCA1 and BRCA2 variants in multi-ethnic Asian cohort from a Malaysian case-control study

[1]  T. Andrews,et al.  Comparison of predicted and actual consequences of missense mutations , 2015, Proceedings of the National Academy of Sciences.

[2]  Nazneen Rahman,et al.  Gene-panel sequencing and the prediction of breast-cancer risk. , 2015, The New England journal of medicine.

[3]  Jingmei Li,et al.  Ethnic Differences in Mammographic Densities: An Asian Cross-Sectional Study , 2015, PloS one.

[4]  D. Pruss,et al.  A comprehensive laboratory‐based program for classification of variants of uncertain significance in hereditary cancer genes , 2014, Clinical genetics.

[5]  K. Kyriacou,et al.  The BRCA1 Variant p.Ser36Tyr Abrogates BRCA1 Protein Function and Potentially Confers a Moderate Risk of Breast Cancer , 2014, PloS one.

[6]  S. Teo,et al.  Prevalence of PALB2 Mutations in Breast Cancer Patients in Multi-Ethnic Asian Population in Malaysia and Singapore , 2013, PloS one.

[7]  Jicheng Li,et al.  BRCA1 Germ‐Line Mutations and Tumor Characteristics in Eastern Chinese Women with Familial Breast Cancer , 2013, Anatomical record.

[8]  C. V. van Asperen,et al.  Variants of Uncertain Significance in BRCA1 and BRCA2 assessment of in silico analysis and a proposal for communication in genetic counselling , 2012, Journal of Medical Genetics.

[9]  Sue Healey,et al.  ENIGMA—Evidence‐based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes , 2012, Human mutation.

[10]  A. Galli,et al.  Effect of the overexpression of BRCA2 unclassified missense variants on spontaneous homologous recombination in human cells , 2011, Breast Cancer Research and Treatment.

[11]  A. Russo,et al.  The Clinical Significance of Unknown Sequence Variants in BRCA Genes , 2010, Cancers.

[12]  P. Bork,et al.  A method and server for predicting damaging missense mutations , 2010, Nature Methods.

[13]  A. Børresen-Dale,et al.  Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study , 2010, Human mutation.

[14]  Anders Albrechtsen,et al.  Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families , 2009, Breast Cancer Research and Treatment.

[15]  S. Sharan,et al.  Mouse embryonic stem cell–based functional assay to evaluate mutations in BRCA2 , 2008, Nature Medicine.

[16]  C. Yip,et al.  Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer , 2008, Breast Cancer Research.

[17]  S. Teo,et al.  BRCA1 and BRCA2 Germline Mutations in Malaysian Women with Early-Onset Breast Cancer without a Family History , 2008, PloS one.

[18]  Giske Ursin,et al.  Evaluation of unclassified variants in the breast cancer susceptibility genes BRCA1 and BRCA2 using five methods: results from a population-based study of young breast cancer patients , 2008, Breast Cancer Research.

[19]  F. Couch,et al.  Classifying Variants of Undetermined Significance in BRCA2 with Protein Likelihood Ratios , 2008, Cancer informatics.

[20]  Fergus J Couch,et al.  A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. , 2007, American journal of human genetics.

[21]  P. V. van Diest,et al.  BRCA1 and BRCA2 germline mutation analysis in the Indonesian population , 2007, Breast Cancer Research and Treatment.

[22]  K.‐R. Lee,et al.  Mutation analysis of BRCA1 and BRCA2 from 793 Korean patients with sporadic breast cancer , 2006, Clinical genetics.

[23]  A. Zharkikh,et al.  Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral , 2005, Journal of Medical Genetics.

[24]  N. Rahman,et al.  A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO , 2004, Journal of Medical Genetics.

[25]  E. Ostrander,et al.  BRCA1 and BRCA2 Mutations in Women from Shanghai China , 2004, Cancer Epidemiology Biomarkers & Prevention.

[26]  B. Ward,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Csilla Szabo,et al.  The Breast Cancer Information Core: Database design, structure, and scope , 2000, Human mutation.

[28]  S. Teo,et al.  Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history , 2014, Breast Cancer Research and Treatment.

[29]  Paolo Radice,et al.  A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity. , 2013, Cancer research.

[30]  Jianjun Liu,et al.  Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families , 2010, Breast Cancer Research and Treatment.

[31]  A. Galli,et al.  A recombination-based method to characterize human BRCA1 missense variants , 2010, Breast Cancer Research and Treatment.

[32]  S. Gruber,et al.  Genetic/familial high-risk assessment: breast and ovarian. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[33]  S. Henikoff,et al.  Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.